Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in China Region

Company Name
Description Under the terms of the agreement, ApolloBio will make an upfront payment of $16 million to Tocagen, plus potential payments of $4 million in near-term development milestones
Global M&A Offices
Hollyhigh International Capital (Global M&A China)
Global M&A Advisory Advisor to the buyer